The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 onglycemia in the critically Ill

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3333-3336

  Lee, Michael Y ^a   Fraser, Jonathan D ^b   Chapman, Marianne J ^a,b   Sundararajan, Krishnaswamy ^a,b   Umapathysivam, Mahesh M ^a   Summers, Matthew J ^b   Zaknic, Antony V ^b   Rayner, Christopher K ^c   Meier, Juris J ^d   Horowitz, Michael ^c   Deane, Adam M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1;

ADD ON THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFUSION; INSULIN LIKE ACTIVITY; INSULIN RESPONSE; MALE; NUTRIENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84891870406     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0307     Document Type: Article

References (15)

1. Deane AM, Horowitz M. Dysglycaemia in the critically illdsignificance and management. Diabetes Obes Metab 2013;15: 792-801
2. Finfer S, Liu B, Chittock DR, et al.; NICESUGAR Study Investigators. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012;367:1108-1118
3. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagonlike peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-917
4. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994;51:63-74
5. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebocontrolled cross over study. Crit Care 2009;13:R67
6. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dosedependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801
7. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagons and insulin secretion in humans. Diabetes 2011;60:3103-3109
8. Mentis N, Vardarli I, Köthe LD, et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 2011;60:1270-1276
9. Deane AM, SummersMJ, Zaknic AV, et al. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care 2011;15: R35
10. Deane AM, Chapman MJ, Fraser RJ, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit CareMed 2010; 38:1261-1269
11. Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 2011;300:E1038-E1046
12. Vilsbøll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucosedependent insulinotropic polypeptideregardless of etiology and phenotype. J Clin Endocrinol Metab 2003;88:4897-4903
13. Zhou J, Livak MF, Bernier M, et al. Ubiquitination is involved in glucose-mediated downregulation of GIP eceptors in islets. Am J Physiol Endocrinol Metab 2007; 293:E538-E547
14. Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009;52:199-207
15. Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009; 58:1342-1349